Blood-stage vaccine development is particularly critical for Plasmodium vivax. Large-scale protein arrays are powering an expansion in vaccine antigen screening. Structural studies allow antigen design to focus on critical pan-reactive epitopes. Further information on immune mechanisms and antigen diversity is needed.